SCHEMBL1865742

SCHEMBL1865742

O=C(O)N1CCC(=Cc2cc(F)c([N+](=O)[O-])cc2F)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 4/20 0.41
CASP3 P42574 1/20 0.41
USP14 P54578 1/20 0.41
UCHL5 Q9Y5K5 1/20 0.41
MAPT P10636 7/20 0.38
ALDH1A1 P00352 3/20 0.38
GPR174 Q9BXC1 4/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1872138 0.89 CASP3 (0.39) SRD5A2CASP3USP14UCHL5MAPT
SCHEMBL22556898 0.85 MAPT (0.39) SRD5A2CASP3USP14UCHL5MAPT
SCHEMBL1869807 0.83 MAPT (0.45) CASP3USP14UCHL5MAPTALDH1A1
SCHEMBL1863164 0.82 CASP3 (0.47) SRD5A2CASP3USP14UCHL5MAPT
SCHEMBL1866587 0.77 SRD5A2 (0.40) SRD5A2CASP3USP14UCHL5MAPT
SCHEMBL5347699 0.76 ERN1 (0.53) MAPTALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL22556714 0.75 TSHR (0.47) MAPTALDH1A1SMN1; SMN2LMNACYP2C9
SCHEMBL6822675 0.75 CASP3 (0.41) CASP3USP14UCHL5MAPTALDH1A1
SCHEMBL3579559 0.74 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL1870418 0.73 MAPT (0.42) MAPTALDH1A1GPR174SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 SRD5A2 194/4885CASP3 922/4885USP14 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.